Amoéba S.A. (LON:0RAE)

London · Delayed Price · Currency is GBP · Price in EUR

0.7750

+0.0155 (2.04%)

At close: Jun 25, 2026

-19.55% (1Y)

Market Cap	45.24M -0.7%
Revenue (ttm)	606.69K +15.6%
Net Income	-7.24M
EPS	-0.12
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	28
Open	0.7750
Previous Close	0.7595
Day's Range	0.7750 - 0.7750
52-Week Range	0.7450 - 1.1920
Beta	0.25
Analysts	n/a
Price Target	n/a
Earnings Date	Apr 17, 2026

About Amoéba

Amoéba S.A. develops biological products and services for the treatment of microbiological risk in the sectors of water, health, and plant protection in France. The company has developed technology to treat water, surfaces, and chronic wounds that uses the natural biocidal capacity of the living amoeba Willaertia magna C2c Maky; and agriculture biocontrol technology for the treatment of phytopathogenic microorganisms using the lysed. Amoéba S.A. was incorporated in 2010 and is headquartered in Chassieu, France. [Read more]

Industry Miscellaneous Chemical Products

Founded 2010

Employees 23

Stock Exchange London Stock Exchange

Ticker Symbol 0RAE

Financial Performance

In 2025, Amoéba's revenue was 695,449, an increase of 15.60% compared to the previous year's 601,600. Losses were -8.30 million, 26.0% more than in 2024.

Financial numbers in EUR Financial Statements